Akebia Therapeutics Q3 revenue misses on lower Auryxia sales
AKBA•Akebia Therapeutics reported third-quarter revenue of $36.90 million, below the $46.94 million analyst consensus, and swung to a net loss of $14.35 million. The company said lower Auryxia sales reflected generic competition and pricing pressure.
1. Quarterly results
Akebia Therapeutics reported third-quarter revenue of $36.90 million, compared with analyst expectations of $46.94 million. It swung to a net loss of $14.35 million, versus estimates of $9.63 million, and reported a loss per share of $0.05 against a $0.04 estimate.
2. Sales and outlook
The company attributed the revenue decline to lower Auryxia sales amid generic competition and pricing pressure. It expects Auryxia revenue to continue decreasing in 2026. Third-quarter Vafseo revenue was affected by inventory reduction at its largest customer and market dynamics as TDAPA expiration approaches.
3. Pipeline expectations
Akebia anticipates Vafseo access will expand in 2027 beyond TDAPA-only patients to nearly all eligible patients. It expects to report initial data from its Phase 2 ebribafusp alfa trial in 2027.
